Physician profile
Boma Park
NPI 1730363623
$4,712.02
in general payments reported to CMS, 2019-2025
22 companies · $313 in 2025
The $313 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $257 · 2020: $255 · 2021: $491 · 2022: $1,544 · 2023: $1,054 · 2024: $797 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,164.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,050.90 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $543.72 | 2022-2024 | |
| Esperion Therapeutics, INC. | $412.28 | 2022 | |
| Abbvie INC. | $258.19 | 2020-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $249.89 | 2022-2024 | Jardiance |
| Glaxosmithkline, LLC. | $158.88 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Heartflow, INC. | $153.98 | 2024 | |
| Lilly USA, LLC | $152.41 | 2022-2024 | Jardiance |
| Amgen INC. | $146.69 | 2024 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $138.53 | 2019-2025 | Breztri |
| Vanda Pharmaceuticals INC. | $111.46 | 2020-2021 | |
| Azurity Pharmaceuticals, INC. | $66.36 | 2023-2025 | Edarbi, Edarbi |
| Amarin Pharma, INC. | $53.87 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $40.06 | 2023 | Quviviq |
| Gilead Sciences, INC. | $32.66 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $31.94 | 2023 | Accrufer |
| Alk-Abello, INC | $22.36 | 2024 | Ragwitek, Odactra, Grastek |
| Cequr Corporation | $20.89 | 2023 | Cequr Simplicity |
| Merck Sharp & Dohme LLC | $18.88 | 2020 | |
| Shire North American Group INC | $18.35 | 2019 | |
| Phathom Pharmaceuticals, INC. | $17.87 | 2025 | Voquezna |
| Horizon Therapeutics Plc | $11.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Boma Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.